Argo et al., 2015 [27] |
34 |
NASH |
Obese |
3000 mg |
12 months |
Placebo |
35% EPA + 250% DHA + 10% other n-3s |
Liver biopsy + haematochemical |
Scorletti et al., 2014 [28] |
103 |
NAFLD |
Obese |
4000 mg |
15–18 months |
Placebo |
46% EPA + 38% DHA |
Liver biopsy or imaging evidence or features of MetS |
Sanyal et al., 2014 [29] |
119 |
NASH/NAFLD |
Obese |
2700 mg |
12 months |
Placebo |
Highly purified EPA ethyl ester |
Liver biopsy + haematochemical |
Sofi et al., 2010 [30] |
11 |
NAFLD |
Obese |
830 mg |
12 months |
Placebo |
56.6% EPA + 28.9% DHA |
Ultrasonography + haematochemical |
Dasarathy et al., 2015 [31] |
37 |
NASH with diabetes |
Obese |
3600 mg |
12 months |
without treatment |
60% EPA + 40% DHA |
Liver biopsy + haematochemical |
Zhu et al., 2008 [2] |
134 |
NAFLD |
Obese |
2000 mg |
24 weeks |
Placebo |
Seal oils |
Ultrasonography + haematochemical |
Spadaro et al., 2008 [32] |
36 |
NAFLD |
Obese |
2000 mg |
6 months |
Without treatment |
Not mentioned |
Ultrasonography + haematochemical |
Capanni et al., 2006 [33] |
56 |
NAFLD |
Obese |
1000 mg |
12 months |
Placebo |
37.5% EPA + 62.5% DHA |
Ultrasonography + haematochemical |
Vega et al., 2008 [34] |
16 |
Subset of DHS cohort |
Obese |
9000 mg |
8 wk |
Placebo |
51.4% C20:5, 23.9% C22:6 |
Elevated HTGC (MRS) + average ALT within reference range |
Chen et al. 2008 [35] |
46 |
NAFLD |
Not specified |
5000 mg |
24 wk |
Placebo |
Harp seal oil capsules (not specified) |
Elevated LFTs and TGs |